Literature DB >> 2045131

Characterization of C1 inhibitor binding to neutrophils.

N S Chang1, R J Boackle, R W Leu.   

Abstract

In a previous study we have isolated neutrophil membrane proteins that non-covalently bind to native C1-INH (105,000 MW) and a non-functional, degraded C1-INH (88,000 MW; C1-INH-88). To further characterize the binding nature, we have designed a novel kinetic C1 titration assay which enables not only a quantification of the removal of fluid-phase C1-INH by neutrophils, but also a concomitant measure of residual C1-INH function. Native C1-INH, when adsorbed to EDTA-pretreated neutrophils, lost its function in the inhibition of fluid-phase C1. The non-functional C1-INH-88, which is probably devoid of a reactive centre, was found to block the binding of native C1-INH to neutrophils. Pretreatment of neutrophils with serine esterase inhibitors did not abrogate binding capacity of the cells for C1-INH, whereas the binding affinity for C1-INH was lost when the cells were pretreated with trypsin. An array of human peripheral blood leucocytes and several lymphoid cell lines has surface binding sites for C1-INH, but not on human erythrocytes and U937 cells. Binding was further confirmed using (i) C1-INH-microsphere beads to neutrophils, in which the binding was blocked when pretreating neutrophils with excess C1-INH or with trypsin, and (ii) radiolabelled C1-INH to neutrophils, which was competitively blocked by unlabelled non-functional C1-INH-88. Desialylation of C1-INH significantly reduced its binding affinity for neutrophils, indicating that the membrane receptor sites on neutrophils could be specific for the binding of sialic acid residues on C1-INH. Overall, our studies indicate that neutrophils or other leucocytes possess specific surface binding sites for the sialic acid-containing portion of C1-INH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2045131      PMCID: PMC1384524     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Enhancement of migration inhibitory factor activity by plasma esterase inhibitors.

Authors:  H G Remold; R D Rosenberg
Journal:  J Biol Chem       Date:  1975-08-25       Impact factor: 5.157

2.  Effects of human C 1 inhibitor on complement-mediated human leukocyte chemotaxis.

Authors:  C W Smith; J C Hollers; D H Bing; R A Patrick
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

3.  Partial purification of a serum inhibitor of C'1-esterase.

Authors:  J PENSKY; L R LEVY; I H LEPOW
Journal:  J Biol Chem       Date:  1961-06       Impact factor: 5.157

4.  Measurement of C1 inactivator (alpha 2 neuraminoglycoprotein) on human blast cells in blast leukaemia.

Authors:  K Osther; R Linnemann
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-04

5.  Demonstration of a complement of inactivator on cultured cells from human malignant brain tumours.

Authors:  K Osther; K Hojgaard; E Dybkjaer
Journal:  Acta Neurol Scand       Date:  1974       Impact factor: 3.209

6.  Immunofluorescence measurement of C1 inactivator (alpha 2 neuraminoglycoprotein) activity of the surface of human carcinoma cells.

Authors:  K Osther; R Linnemann
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-06

7.  [Isolation and characterization of C1-Inactivator from human plasma].

Authors:  H Haupt; N Heimburger; T Kranz; H G Schwick
Journal:  Eur J Biochem       Date:  1970-12

8.  The interactions of human complement with interfacially aggregated preparations of human secretory IgA.

Authors:  R J Boackle; K M Pruitt; J Mestecky
Journal:  Immunochemistry       Date:  1974-09

9.  Plasma inhibitors of the components of the fibrinolytic pathway in man.

Authors:  A D Schreiber; A P Kaplan; K F Austen
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

2.  Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Authors:  E Eldering; C C Huijbregts; J H Nuijens; A J Verhoeven; C E Hack
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

3.  Human C1-Inhibitor Suppresses Malaria Parasite Invasion and Cytoadhesion via Binding to Parasite Glycosylphosphatidylinositol and Host Cell Receptors.

Authors:  Pedro Mejia; Monica Diez-Silva; Faustin Kamena; Fengxin Lu; Stacey M Fernandes; Peter H Seeberger; Alvin E Davis; James R Mitchell
Journal:  J Infect Dis       Date:  2015-09-07       Impact factor: 5.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.